This Insulet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded BAER, NYT, CRK, PODD and SMMT, lowering price targets for four and adopting more cautious outlooks.
Last updated: 2026-11-19 02:46:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summit Therapeutics Inc. (SMMT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.50, with a market capitalization of $9.45B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.17 to $29.23. This page covers its latest market performance, valuation, price trends and company information.
$9.45B | |
$10.24 | |
$11.36 | |
$10.17 | |
$10.67 | |
11.22M | |
6.56M | |
-- | |
$29.23 | |
$10.17 | |
-- | |
2026-09-30 |
Summit Therapeutics Inc. (SMMT) last closed at $10.50 as of 2026-11-19 00:59:00, down 1.69% ($0.18) from the previous close of $10.67.
During the latest regular trading session, SMMT traded between $10.17 and $11.36, with a volume of 11.22M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Summit Therapeutics Inc. (SMMT) moved from $17.84 to $10.50, representing a decline of 41.17% ($7.35).
The stock traded between $10.17 and $18.15 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 8.96 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.7%
SMMT is currently trading at $10.50, placing it 1.7% of the way from its 52-week low of $10.17 to its 52-week high of $29.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 265 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Summit Therapeutics Inc. and SMMT stock.
Analysts downgraded BAER, NYT, CRK, PODD and SMMT, lowering price targets for four and adopting more cautious outlooks.
Bernstein analyst Jeffrey Walch downgrades Summit Therapeutics (NASDAQ:SMMT) from Market Perform to Underperform and lowers the price target from $11.9 to $8.3.
The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following
Salesforce, ServiceNow and Intuit drag software lower ahead of Anthropic's IPO. Treasury yields slip, and Nvidia reports after the bell.
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $43 to $42.
Eligible investors can buy real shares of Summit Therapeutics Inc. (SMMT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to SMMT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between SMMT shares and USD.
SMMT Shares to USD
1.00 SMMT shares = 10.495 USD
Calculations are estimates based on the latest available price and are for reference only.